

Package insert for the AMP/mAMP/COC/OPI/THC/BZO/OXY/MTD/BAR/BUP/COT/MDMA test for oral fluids. A rapid, screening test for the simultaneous, qualitative detection of Amphetamine, Methamphetamine, Cocaine, Opiate, Marijuana, Benzodiazepines, Oxycodone, Methadone, Barbiturates, Buprenorphine, Cotinine, Methylenedioxymethamphetamine and their metabolites in human oral fluid.

For Forensic Use, Employment Use and Insurance Testing Use Only

INTENDED USE

The **STAT SWAB®** Oral Fluid Drug Screen Device for AMP/mAMP/COC/OPI/THC/BZO/OXY/MTD/BAR/BUP/ COT/MDMA is a lateral flow chromatographic immunoassay for the qualitative detection of Amphetamine, Methamphetamine, Cocaine, Opiate, Marijuana, Benzodiazepines, Oxycodone, Methadone, Barbiturates, Buprenorphine, Cotinine, Methylenedioxymethamphetamine and their metabolites in oral fluids at the following cutoff concentrations:

Test	Calibrator	Cut-off			
Amphetamine (AMP)	D-Amphetamine	50 ng/mL			
Methamphetamine (mAMP)	D-Methamphetamine	50 ng/mL			
Cocaine (COC)	Benzoylecgonine	20 ng/mL			
Cocarrie (COC)	Benzoylecgonine	50 ng/mL			
Opiate (OPI)	Morphine	40 ng/mL			
Oplate (OFI)	Morphine	50 ng/mL			
	11-nor-Δ ⁹ -THC-9-COOH	12 ng/mL			
Marijuana (THC)	Δ ⁹ -THC	25 ng/mL			
	Δ ⁹ -THC	50 ng/mL			
	Δ ⁹ -THC	75 ng/mL			
Benzodiazepines (BZO)	Oxazepam	50 ng/mL			
Benzoulazepines (BZO)	Oxazepam	30 ng/mL			
Oxycodone (OXY)	Oxycodone	50 ng/mL			
Methadone (MTD)	Methadone	75 ng/mL			
Barbiturates (BAR)	Secobarbital	300 ng/mL			
Buprenorphine (BUP)	Buprenorphine	10 ng/mL			
Cotinine (COT)	Cotinine	30 ng/mL			
Methylenedioxymethamphetamine (MDMA)	(±)-3,4-Methylenedioxymethamphetamine	50 ng/mL			

This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) and gas chromatography/tandem mass spectrometry (GC/MS/MS) are the preferred confirmatory methods. Professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

This test is limited for forensic use, employment use and insurance testing. This test system shall not be used for Federal drug testing programs.

SUMMARY AND EXPLANATION OF THE TEST

The **STAT SWAB®** Oral Fluid Drug Screen Device for AMP/mAMP/COC/OPI/THC/BZO/OXY/MTD/BAR/BUP/ COT/MDMA and their metabolites is a rapid, oral fluid screening test that can be performed without the use of an instrument. The test utilizes monoclonal antibodies to selectively detect elevated levels of specific drugs in human oral fluid.

AMPHETAMINE (AMP)

Amphetamine is a sympathomimetic amine with therapeutic indications. The drug is often self-administered by nasal inhalation or oral ingestion. Depending on the route of administration, Amphetamine can be detected in oral fluid as early as 5-10 minutes and up to 72 hours after use¹.

The Amphetamine assay contained within the STAT SWAB[®] Oral Fluid Drug Screen Device yields a positive result when the Amphetamine concentration in oral fluid exceeds 50 ng/mL.

METHAMPHETAMINE (mAMP)

Methamphetamine is a potent stimulant chemically related to amphetamine but with greater CNS stimulation properties. The drug is often self-administered by nasal inhalation, smoking or oral ingestion. Depending on the route of administration, methamphetamine can be detected in oral fluid as early as 5-10 minutes and up to 72 hours after use¹.

The Methamphetamine assay contained within the STAT SWAB® Oral Fluid Drug Screen Device yields a positive result when the Methamphetamine concentration in oral fluid exceeds 50 ng/mL.

COCAINE (COC)

Cocaine is a potent central nervous system (CNS) stimulant and a local anesthetic derived from the coca plant (erythroxylum coca). The drug is often self-administered by nasal inhalation, intravenous injection and free-base smoking. Depending on the route of administration, cocaine and metabolites benzoylecgonine and ecgonine methyl ester can be detected in oral fluid so early as 5-10 minutes following use¹. Cocaine and benzoylecgonine can be detected in oral fluids for up to 24 hours after use¹.

The Cocaine assay contained within the **STAT SWAB®** Oral Fluid Drug Screen Device yields a positive result when the Benzoylecgonine concentration in oral fluid exceeds 20 ng/mL.

The Cocaine assay contained within the STAT SWAB[®] Oral Fluid Drug Screen Device yields a positive result when the Benzoylecgonine concentration in oral fluid exceeds 50 ng/mL.

OPIATE (OPI)

The drug class opiates refer to any drug that is derived from the opium poppy, including naturally occurring compounds such as morphine and codeine and semi-synthetic drugs such as heroin. Opiate act to control pain by depressing the central nervous system. The drugs demonstrate addictive properties when used for sustained periods of time; symptoms of withdrawal may include sweating, shaking, nausea and irritability. Opiates can be taken orally or by injection routes including intravenous, intramuscular and subcutaneous; illegal users may also take the intravenously or by nasal inhalation. Using an immunoassay cut-off level of 40 ng/mL, codeine can be detected in the oral fluid within 1 hour following a single oral dose and can remain detectable for 7-21 hours after the dose². 6monoacetyImorphine (6-MAM) is found more prevalently in oral fluid, and is a metabolic product of heroin. Morphine is the major metabolic product of codeine and heroin, and is detectable for 24-48 hours after an opiate dose.

The Opiate assay contained within the STAT SWAB[®] Oral Fluid Drug Screen Device yields a positive result when the Morphine concentration in oral fluid exceeds 40 ng/mL.

The Opiate assay contained within the STAT SWAB[®] Oral Fluid Drug Screen Device yields a positive result when the Morphine concentration in oral fluid exceeds 50 ng/mL.

MARIJUANA (THC)

Tetrahydrocannabinol, the active ingredient in the marijuana plant (cannabis sativa), is detectable in saliva shortly after use. The detection of the drug is thought to be primarily due to the direct exposure of the drug to the mouth (oral and smoking administrations) and the subsequent sequestering of the drug in the buccal cavity³. Historical studies have shown a window of detection for THC in saliva of up to 14 hours after drug use³.

The Marijuana assay contained within the **STAT SWAB[®] Oral Fluid Drug Screen Device** yields a positive result when the 11-nor-Δ⁹-THC-9-COOH concentration in oral fluid exceeds 12 ng/mL.

The Marijuana assay contained within the **STAT SWAB[®]** Oral Fluid Drug Screen Device yields a positive result when the Δ^9 -THC concentration in oral fluid exceeds 25 ng/mL.

The Marijuana assay contained within the **STAT SWAB[®]** Oral Fluid Drug Screen Device yields a positive result when the Δ^9 -THC concentration in oral fluid exceeds 50 ng/mL.

The Marijuana assay contained within the **STAT SWAB**[®] **Oral Fluid Drug Screen Device** yields a positive result when the Δ^9 -THC concentration in oral fluid exceeds 75 ng/mL.

BENZODIAZEPINES (BZO)

Benzodiazepines are frequently prescribed sedative and hypnotic drug for the symptomatic treatment of anxiety, insomnia, sleep and seizure disorders. Most Benzodiazepines are extensively metabolized in the liver and excreted in the urine and saliva as metabolites. Chronic abuse may increase the risk of physical dependence and may result in intoxication, drowsiness and muscle relaxation. Oxazepam is the major metabolic product of Benzodiazepines.

The Benzodiazepines assay contained within the STAT SWAB® Oral Fluid Drug Screen Device yields a positive result when the Oxazepam concentration in oral fluids exceeds 50 ng/mL.

The Benzodiazepines assay contained within the STAT SWAB® Oral Fluid Drug Screen Device yields a positive result when the Oxazepam concentration in oral fluids exceeds 30 ng/mL.

OXYCODONE (OXY)

Oxycodone is a semi-synthetic opioid with a structural similarity to codeine. The drug is manufactured by modifying thebaine, an alkaloid found in the opium poppy. Oxycodone, like all opiate agonists, provides pain relief by acting on opioid receptors in the spinal cord, brain, and possibly directly in the affected tissues. Oxycodone is prescribed for the relief of moderate to high pain under the well-known pharmaceutical trade names of OxyContin®, Tylox®, Percodan® and Percocet®. While Tylox, Percodan and Percocet contain only small doses of oxycodone hydrochloride combined with other analgesics such as acetaminophen or aspirin, OxyContin consists solely of oxycodone hydrochloride in a time-release form.

The Oxycodone assay contained within the STAT SWAB® Oral Fluid Drug Screen Device yields a positive result when the Oxycodone concentration in oral fluid exceeds 50 ng/mL.

METHADONE (MTD)

Methadone is a narcotic analgesic prescribed for the management of moderate to severe pain and for the treatment of opiate dependence (heroin, Vicodin, Percocet, morphine). The pharmacology of oral methadone is very different from IV methadone. A roll methadone is partially stored in the liver for later use. IV methadone acts more like heroin. In most states you must go to a pain clinic or a methadone maintenance clinic to be prescribed methadone. Methadone is a long acting pain reliever producing effects that last from twelve to forty-eight hours. Ideally, methadone frees the client from the pressures of obtaining illegal heroin, from the dangers of injection, and from the emotional roller coaster that most opiates produce. Methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists⁵.

The Methadone assay contained within the STAT SWAB[®] Oral Fluid Drug Screen Device yields a positive result when the Methadone concentration in oral fluids exceeds 75 ng/mL.

BARBITURATES (BAR)

Barbiturates are CNS depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants. Barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of barbiturates leads to tolerance and physical dependence.

Short-acting barbiturates taken at 400 mg/day for 2-3 months can produce a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.

The approximate detection time limits for barbiturates are:

Short acting (e.g. Secobarbital) 100 mg PO (oral) 4.5 days Long acting (e.g. Phenobarbital) 400 mg PO (oral) 7 days⁵

The Barbiturates assay contained within the STAT SWAB® Oral Fluid Drug Screen Device yields a positive result when the Secobarbital concentration in oral fluid exceeds 300 ng/mL.

BUPRENORPHINE (BUP)

Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is sold under the trade names Subutex[™], Buprenex[™], Temgesic[™] and Suboxone[™], which contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therapy, Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence.

Substantial abuse of Buprenorphine has also been reported in many countries where various forms of the drug are available. The drug has been diverted from legitimate channels through theft, doctor shopping, and fraudulent prescriptions, and been abused via intravenous, sublingual, intransaal and inhalation routes.

The Buprenorphine assay contained within the STAT SWAB[®] Oral Fluid Drug Screen Device yields a positive result when the Buprenorphine concentration in oral fluid exceeds 10 ng/mL.

COTININE (COT)

Cotinine ((5S)-1-methyl-5-(3-pyridyl)pyrrolidin-2-one) is a first-stage metabolite of nicotine, an alkaloid that stimulates the autonomic ganglia and central nervous system in humans. Nicotine is a drug to which virtually every member of a tobacco-smoking society is exposed whether through direct contact or second-hand inhalation. Aside from tobacco, nicotine is also commercially available as the active ingredient in smoking replacement therapies such as nicotine oum transdermal patches and pasal sprays. Once converted from Nicotine, Cotinine has an in vivo half-life in human body for approximately 20 hours and is typically detectable for several days and up to one week after the use of tobacco. The level of cotinine in the blood, urine or saliva is proportionate to the amount of exposure to tobacco smoke. Cotinine, therefore, is a valuable indicator of tobacco smoke exposure, including secondary or passive smoke. People who smoke menthol cigarettes may retain cotinine in the blood for a longer period because menthol can compete with enzymatic metabolism of cotinine⁶. Genetic encoding of liver enzymes may also play a role, as people of African descent routinely register higher blood cotinine levels than Caucasians⁷. Cotinine levels <10 ng/mL are considered to be consistent with no active smoking. Values of 10 ng/mL to 100 ng/mL are associated with light smoking or moderate passive exposure, and levels above 300 ng/mL are seen in heavy smokers who smoke more than 20 cigarettes a day. Values between 11 ng/mL and 30 ng/mL may be associated with light smoking or passive exposure, and levels in active smokers typically reach 500 ng/mL or more. Cotinine assays provide an objective quantitative measure that is more reliable than smoking histories or counting the number of Cotinine also permits the measurement of exposure to second-hand smoke or passive smoking. Various types of drug tests can detect cotinine in the blood, urine, or saliva. Cotinine level in saliva has been found to be the best marker for smoking status compared with saliva nicotine measurements, breath carbon monoxide testing and plasma thiocyanate testing⁸.

The Cotinine assay contained within the STAT SWAB® Oral Fluid Drug Screen Device yields a positive result when the Cotinine concentration in oral fluid exceeds 30 ng/mL.

METHYLENEDIOXYMETHAMPHETAMINE (MDMA)

Methylenedioxymethamphetamine (ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the treatment of obesity. Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and blurred vision in some users. Its mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, although the general opinion is that this is a secondary effect of the drug (Nichols and Oberlender, 1990). The most pervasive effect of MDMA, occurring in virtually all people who took a reasonable dose of the drug, was to produce a clenching of the jaws.

The Methylenedioxymethamphetamine assay contained within the STAT SWAB® Oral Fluid Drug Screen Device yields a positive result when the Methylenedioxymethamphetamine concentration in oral fluid exceeds 50 ng/mL.

PRINCIPLE

The **STAT SWAB®** Oral Fluid Drug Screen Device for AMP/mAMP/COC/OPI/THC/BZO/OXY/MTD/BAR/BUP/ COC/MDMA is an immunoassay based on the principle of competitive binding. Drugs that may be present in the oral fluid specimen compete against their respective drug conjugate for binding sites on their specific antibody.

During testing, a portion of the oral fluid specimen migrates upward by capillary action. A drug, if present in the oral fluid specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration in the oral fluid specimen will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test line region.

A drug-positive oral fluid specimen will not generate a colored line in the specific test line region of the strip because of drug competition, while a drug-negative oral fluid specimen will generate a line in the test line region because of the absence of drug competition. To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

REAGENT

The test contains membrane strips coated with drug-protein conjugates (purified bovine albumin) on the test line, a goat polyclonal antibody against gold-protein conjugate at the control line, and a dye pad which contains colloidal gold particles coated with mouse monoclonal antibody specific to Amphetamine, Methamphetamine, Benzoylecgonine, Morphine, Marijuana, Oxazepam, Oxycodone, Methadone, Secobarbital, Buprenorphine, Cotinine and Methylenedioxymethamphetamine.

PRECAUTIONS

- · For forensic use, employment use and insurance testing use only.
- Do not use after the expiration date.
- The oral fluid drug screen device should remain in the sealed pouch until use.
- Saliva is not classified as biological hazard unless derived from a dental procedure.
- The test device is for single use.
- The used collector and device should be discarded according to federal, state and local regulations.

STORAGE AND STABILITY

Store as packaged in the sealed pouch at 2-30°C. The test is stable through the expiration date printed on the sealed pouch. The test devices must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

SPECIMEN COLLECTION AND PREPARATION

The oral fluid specimen should be collected using the collector provided with the kit. Follow the detailed Directions for Use below. No other collection devices should be used with this assay. Oral fluid collected at any time of the day may be used.

MATERIALS

Materials Provided

• Test devices

• Package insert


• Procedure card
Materials Required But Not Provided

• Timer

DIRECTIONS FOR USE

Allow the test device to reach room temperature [15-30°C (59-86°F)] prior to testing. Do not place anything in the mouth including food, drink, gum, or tobacco products for at least 10 minutes prior to collection of oral fluid specimen.

- 1. Remove the collection stick and test tube from the sealed pouch.
- 2. Tear off the package of the collection stick. (Step 1)
- 3. Insert the sponge end of the collection stick into mouth and soak sponge into saliva for 3 minutes. (Note: Time should be longer for people of little saliva. If the amount of saliva pressed into the test tube is not adequate for testing, collect more with another new collection stick and express the saliva into tube again.) (Step 2)
- 4. Hold the test tube vertically and place the collection stick with saturated sponge into the test tube. Make sure to fit the groove of collection stick onto the guide rail of test tube and press the collection stick to full extent. (Step 3)
- 5. Press down the lid to close the test tube. Keep the test tube vertically until you begin to read the test results. (Step
- Read results of drug tests at 10 minutes. (If there is a label over reading window, peel off the label to read test results.) Do not read drug tests results after 1 hour. (Step 5)
- 7. Send the collector with collected oral fluid to the laboratory for GC/MS confirmation if necessary.



INTERPRETATION OF RESULTS

(Please refer to the previous illustration)

NEGATIVE:

Two lines appear. * One color line should be in the control region (C), and another apparent color line adjacent should be in the test region (T). This negative result indicates that the drug concentration is below the detectable level. *NOTE: The shade of color in the test line region (T) will vary, but it should be considered negative whenever there is even a faint distinguishable color line.

POSITIVE:

One color line appears in the control region (C). No line appears in the test region (T). This positive result indicates that the drug concentration is above the detectable level.

INVALID:

Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test device. If the problem persists, discontinue using the lot immediately and contact your supplier.

QUALITY CONTROL

A procedural control is included in the test. A color line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

LIMITATIONS

 The STAT SWAB[®] Oral Fluid Drug Screen Device provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) or gas chromatography/tandem mass spectrometry (GC/MS/MS) is preferred confirmatory methods.

- A positive test result does not indicate the concentration of drug in the specimen or the route of administration.
 A negative result may not necessarily indicate a drug-free specimen. Drug may be present in the specimen below
- the cut-off level of the assay. 4. The test has been developed for testing saliva samples only. No other fluids have been evaluated. Do NOT use
- The test has been developed for testing samples only. No other hulds have been evaluated. Do NOT use this device to test anything but saliva.

PERFORMANCE CHARACTERISTICS

Analytical Sensitivity

A phosphate-buffered saline (PBS) pool was spiked with drugs to target concentrations of ± 50% cut-off and ± 25% cut-off and tested with the **STAT SWAB[®]** Oral Fluid Drug Screen Device. The results are summarized below.

Drug Concentration	n	AM	ΛP	mA	MP	CC)C	0	PI	Tł	IC	BZ	20	0)	Υ	M	D	BA	١R	BL	JP	CC	DT	MD	MA
Cut-off Range			+		+		+	-	+		+		+		+		+		+		+		+		+
0% Cut-off	30	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	30	28	2	29	1	30	0	27	3	27	3	28	2	28	2	29	1	29	1	27	3	29	1	29	1
Cut-off	30	13	17	16	14	19	11	18	12	14	16	13	17	12	18	10	20	12	18	16	14	20	10	5	25
+25% Cut-off	30	4	36	7	23	5	25	3	37	1	29	4	26	3	27	2	28	3	27	7	23	7	23	0	30
+50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Analytical Specificity

The following table lists the concentration of compounds (ng/mL) above which the **STAT SWAB®** Oral Fluid Drug Screen Device for AMP/mAMP/COC/OPI/THC/BZO/OXY/MTD/BAR/BUP/COT/MDMA identified positive results at a read time of 10 minutes.

Drug	Concentration (ng/mL)						
AMPHETAMINE (AMP)							
D-Amphetamine	50						
DL-Amphetamine	125						
β-Phenylethylamine	4,000						
(+)3,4-Methylenedioxyamphetamine (MDA)	150						
L-Amphetamine	4,000						
p-Hydroxyamphetamine	800						
Tryptamine	1,500						
Tyramine	1,000						
METHAMPHETAMINE (mAMP)							
D-Methamphetamine	50						
(1R,2S)-(-)-Ephedrine	400						
Fenfluramine	60,000						
Methoxyphenamine	25,000						
3,4-Methylenedioxymethamphetamine	50						
p-Hydroxymethamphetamine	400						
L-Phenylephrine	4,000						
Procaine	2,000						
COCAINE (COC 20)							
Benzoylecgonine	20						
Cocaine HCI	20						
Cocaethylene	25						
Ecgonine HCI	1,500						
Ecgonine Methyl Ester	12,500						

Benzoylecgonine	50
Cocaine HCI	20
Cocaethylene	25
Ecgonine HCI	1,500
Ecgonine Methyl Ester	12,500
	12,500
OPIATE (OPI 40)	
Morphine	40
Bilirubin	3,500
Codeine	10
Diacetylmorphine (Heroin)	50
Ethylmorphine	24
Hydrocodone	100
Hydromorphone	100
Levorphanol	400
6-Monoacetylmorphine	25
Morphine 3-β-D-Glucuronide	50
Nalorphine	10,000
Normorphine	12,500
Norcodeine	1,500
Oxycodone	25,000
Oxymorphone	25,000
Thebaine	1,500
OPIATE (OPI 50)	
Morphine	50
Bilirubin	3,500
Codeine	10
Diacetylmorphine (Heroin)	50
Ethylmorphine	24
Hydrocodone	100
Hydromorphone	100
	400
Levorphanol	
6-Monoacetylmorphine	25
Morphine 3-β-D-Glucuronide	50
Nalorphine	10,000
Normorphine	12,500
Norcodeine	1,500
Oxycodone	25,000
Oxymorphone	25,000
Thebaine	1,500
BENZODIAZEPINES (BZO 50)	
α-Hydroxyalprazolam	1,260
Alprazolam	40
Bromazepam	400
Chlordiazepoxide	780
Chlordiazepoxide HCI	390
Clobazam	100
Clonazepam	785
Clorazepate Dipotassium	195
Delorazepam	1,560
Desalkylflurazepam	390
Diazepam	195
Estazolam	2,500
Flunitrazepam	385
(±) Lorazepam	1,560
RS-Lorazepam Glucuronide	160
Midazolam	12,500
	95
Nitrazepam	
Norchlordiazepoxide	200
Nordiazepam	390
Oxazepam	50
Temazepam	20
Triazolam	2,500
BENZODIAZEPINES (BZO 30)	
α-Hydroxyalprazolam	756
Alprazolam	24
Bromazepam	240
Chlordiazepoxide	468
Chlordiazepoxide HCI	
	234
Clobazam	<u> 60</u>
Clonazepam Clorazepate Dipotassium	117

COCAINE (COC 50)

Delement	
Delorazepam	936
Desalkylflurazepam	234
Diazepam	117
Estazolam	1,500
Flunitrazepam	231
(±) Lorazepam	936
RS-Lorazepam Glucuronide	96
Midazolam	7,500
Nitrazepam	57
Norchlordiazepoxide	120
Nordiazepam	234
Oxazepam	30
Temazepam	12
Triazolam	1,500
OXYCODONE (OXY)	
Oxycodone	50
Codeine	25,000
Dihydrocodeine	6,250
Ethylmorphine	12,500
Hydrocodone	1,000
Hydromorphone	6,250
Oxymorphone	1,000
Thebaine	25,000
MARIJUANA (THC 25)	
$11-\text{nor-}\Delta^9$ -THC-9-COOH	12
Cannabinol	2,000
	25
Δ ⁹ -THC	
	25
MARIJUANA (THC 50)	
11-nor-∆ ⁹ -THC-9-COOH	12
Cannabinol	2,000
Δ ⁸ -THC	50
Δ ⁹ -THC	50
MARIJUANA (THC 75)	
11-nor-Δ ⁹ -THC-9-COOH	12
Cannabinol	3,000
Δ ⁸ -THC	75
Δ ⁹ -THC	75
	10
METHADONE (MTD)	
Methadone	75
Doxylamine	12,500
Doxylamine	12,500
BARBITURATES (BAR)	
	450
Alphenal	150
Amobarbital	300
Aprobarbital	200
Butabarbital	75
Butalbital	2,500
Butethal	100
Cyclopentobarbital	600
Pentobarbital	300
Phenobarbital	100
Secobarbital	300
BUPRENORPHINE (BUP)	
Buprenorphine	10
Norbuprenorphine	20
Buprenorphine 3-D-Glucuropide	15
Buprenorphine 3-D-Glucuronide	15
Buprenorphine 3-D-Glucuronide Norbuprenorphine 3-D-Glucuronide	15 200
Norbuprenorphine 3-D-Glucuronide	
Norbuprenorphine 3-D-Glucuronide COTININE (COT)	200
Norbuprenorphine 3-D-Glucuronide COTININE (COT) (-)Cotinine	200
Norbuprenorphine 3-D-Glucuronide COTININE (COT) (-)Cotinine S-(-)-Nicotine	200 30 6,250
Norbuprenorphine 3-D-Glucuronide COTININE (COT) (-)Cotinine	200
Norbuprenorphine 3-D-Glucuronide COTININE (COT) (-)Cotinine S-(-)-Nicotine L-Glutathione Reduced	200 30 6,250
Norbuprenorphine 3-D-Glucuronide COTININE (COT) (-)Cotinine S-(-)-Nicotine L-Glutathione Reduced METHYLENEDIOXYMETHAMPHETAMINE (MDMA)	200 30 6,250
Norbuprenorphine 3-D-Glucuronide COTININE (COT) (-)Cotinine S-(-)-Nicotine L-Glutathione Reduced METHYLENEDIOXYMETHAMPHETAMINE (MDMA) (±)-3,4-Methylenedioxymethamphetamine	200 30 6,250
Norbuprenorphine 3-D-Glucuronide COTININE (COT) (-)Cotinine S-(-)-Nicotine L-Glutathione Reduced METHYLENEDIOXYMETHAMPHETAMINE (MDMA)	200 30 6,250 40,000
Norbuprenorphine 3-D-Glucuronide COTININE (COT) (-)Cotinine S-(-)-Nicotine L-Glutathione Reduced METHYLENEDIOXYMETHAMPHETAMINE (MDMA) (±)-3,4-Methylenedioxymethamphetamine	200 30 6,250 40,000 50
Norbuprenorphine 3-D-Glucuronide COTININE (COT) (-)Cotinine S-(-)-Nicotine L-Glutathione Reduced METHYLENEDIOXYMETHAMPHETAMINE (MDMA) (±)-3,4-Methylenedioxymethamphetamine Dobutamine Hydrochloride	200 30 6,250 40,000 50 60,000

INTERFERENCE

A study was conducted to determine the cross-reactivity of the test with compounds spiked into drug-free PBS stock. The following compounds demonstrated no false positive results on the **STAT SWAB[®]** Oral Fluid Drug Screen Device when tested with concentrations up to 100 µg/mL.

Amphetamine, Methamphetamine, Cocaine, Opiate, Marijuana, Benzodiazepines, Oxycodone, Methadone, Barbiturates and Buprenorphine Non-Cross-Reacting Compounds Are: *Parent compound only:

Chlorothiazide **DL-Chlorpheniramine** Chlorpromazine Chloroquine Chlorothiazide Norethindrone D-Norpropoxyphene Noscapine **DL-Octopamine** Creatinine Deoxycorticosterone Dextromethorphan Diclofenac Diflunisal Diaoxin Diphenhydramine L-Ψ-Ephedrine β-Estradiol . Estrone-3-Sulfate Ethyl-p-Aminobenzoate L-(-)-Epinephrine Erythromycin Fenoprofen Furosemide Gentisic Acid Hemoglobin Hydralazine Hydrochlorothiazide Hvdrocortisone o-Hydroxyhippuric Acid p-Hydroxytyramine Ibuprofen Iproniazid DL-Isoproterenol Isoxsuprine Ketamine Ketoprofen Labetalol Loperamide Meperidine Methylphenidate Nalidixic Acid Naloxone Naltrexone Naproxen Niacinamide Nifedipine Oxalic Acid Oxolinic Acid Oxymetazoline Papaverine Penicillin-G Pentazocine Hvdrochloride Perphenazine Phenelzine Trans-2-Phenylcyclopropylamine Hydrochloride Phenylpropanolamine Prednisolone Prednisone DL-Propranolol D-Propoxyphene D-Pseudoephedrine Quinacrine Quinine Quinidine Ranitidine Salicylic Acid Serotonin Sulfamethazine Sulindac Tetracycline Tetrahydrocortisone 3-Acetate

Tetrahydrocortisone 3 (β-D-Glucuronide) Thiamine Thioridazine DL-Tyrosine Tolbutamide Triamterene Trifluoperazine Trimethoprim DL-Tryptophan Uric Acid Verapamil Zomepirac Cotinine Non-Cross-Reacting Compounds are: *Parent compound only: Acetaminophen Acetophenetidin N-Acetylprocainamide Acetylsalicylic Acid Amoxicillin Amphetamine Sulfate Ampicillin L-Ascorbic Acid Apomorphine Aspartame Atropine Cholesterol Clonidine Codeine Cortisone Benzovlecaonine Benzoic Acid Benzphetamine Caffeine Chloramphenicol Chlorothiazide Chlorpromazine Chloroquine Cocaine Hydrochloride Norethindrone D-Norpropoxyphene Noscapine DL-Octopamine Creatinine Dextromethorphan Diflunisal Digoxin L-Ψ-Ephedrine β-Estradiol . Estrone-3-Sulfate Ethyl-p-Aminobenzoate L-(-)-Epinephrine Erythromycin Fenoprofen Furosemide Gentisic Acid Hemoglobin Heroin Hydralazine Hydrochlorothiazide Hydrocortisone Ibuprofen Isoxsuprine Ketamine Labetalol Loperamide Methadone Methamphetamine Meperidine Meprobamate

Methylphenidate Morphine Nalidixic Acid Naloxone Naltrexone Naproxen Niacinamide Oxymetazoline Papaverine Penicillin-G Perphenazine Phencyclidine Phenelzine Hvdrochloride Phenylpropanolamine Prednisolone Prednisone DL-Propranolol D-Propoxyphene D-Pseudoephedrine Quinacrine Quinine Oxycodone Ranitidine Secobarbital Salicylic Acid Serotonin Sulfamethazine Sulindac Tetracvcline Thiamine Thioridazine **DL-Tyrosine** Tolbutamide Trifluoperazine Trimethoprim DL-Tryptophan Tyramine Uric Acid Verapamil Zomepirac Methylenedioxymethamphetamine Non-Cross-Reacting Compounds are: *Parent compound only: Acebutolol Hydrochloride Acetopromazine-d6 Hydrochloride Acetylcysteine Acetylsalicylic Acid (Aspirin) Acetaminophen o6-Acetvlmorphine Acetazolamide N-Acetylprocainamide Acetone Acetophenetidin Alprenolol Hydrochloride Alprazolam Allopurinol Alphenal Amiloride Hydrochloride Aminophenazone (4-Dimethylaminoantipyrine) Amiodarone Hydrochloride Amoxicillin Ampicillin (Ampicinine) Amitriptyline Hydrochloride Aminophylline Amantadine Hydrochloride Amphotericin B Ammonium Amobarbital Amikacin Hydrate Amikacin Sulfate 4-Aminobenzoic Acid DL-Aminoglutethimide Kanamycin Sulfate Aniline Hydrochloride Antipyrine R-(-)-Apomorphine Hydrochloride Hemihydrate Aprobarbital

Aspartame

L-Ascorbic Acid L-Aspartic Acid D-Aspartic Acid **DL-Aspartic Acid** Atropine Sulfate Baclofen Benzphetamine Barbituric Acid **Betamethasone** Berberine Hydrochloride Beclomethasone Dipropionate Aerosol Benzilic Acid Benzocaine Benzyl Alcohol Benzoylecgonine Bendroflumethiazide Benzylamine Hydrochloride Benzoic Acid Bisacodvl Bromazepam Bromocriptine Mesylate Bupivacaine Hydrochloride Buprenorphine Buspirone Hydrochloride Butacaine Butalbital **Butabarbital** Buprenorphine-3-β-D-Glucuronide Butyrophenone Butethal Cannabidiol Caffeine Carbamazepine Carisoprodol Cefaclor Cefradine Ceftriaxone Sodium Cefotaxime Sodium Cefoxitin Cefuroxime Axetil (Zinnat) Cefadroxil Cephradine Chlordiazepoxide HCL Chloroquine Phosphate Chlorpheniramine Maleate Chlorpromazine Hydrochloride Chlorpropamide Chlorprothixene Hydrochloride Chlorthalidone Chlorzoxazone Chloral Hydrate (Trichloroacetaldehyde Hydrate) Cimetidine (-)-Cinchonidine Cinoxacin Cyclosporine Citric Acid Clenbuterol Hydrochloride Clindamycin Clobetasone Butyrate Clomipramine Hydrochloride Clorazepate Dipotassium Clonazepam Clobazam Cloxacillin Colchicine Cholesterol Compound Zinc Undecylenate Triamcinolone Acetonide Ointment (-)-Cotinine Cocaethylene Cocaine Hydrochloride Codeine Creatinine Cyclobenzaprine Hydrochloride Cvclophosphamide L-Cvstine Cyproheptadine Hydrochloride Cyclopentobarbital Dantrolene Sodium Salt Dextromethorphan Hydrobromide Dexamethasone Acetate Deoxyepinephrine Deferoxamine Mesylate

Desipramine Hydrochloride Dimethyl Isosorbide (Isosorbide Dimethyl Ether) Diazepam Diflorasone Diacetate Digoxin Diazoxide Dieldrin Dipyrone Dimethyl Sulfoxide 5,5-Diphenylhydantoin DL-3,4-Dihydroxymandelic Acid Dihydralazine Hemoglobin Disopyramide Dopamine Hydrochloride Doxepin Hydrochloride Doxycycline Hyclate Doxylamine Succinate Salt Droperidol Econine Methyl Ester (±)-Ephedrine Hydrochloride Erythromycin Enteric Eserine Estazolam β-Estradiol . Estriol Estrone Estrone-3-Sulfate Potassium Salt Etoposide Ethacrynic Acid Ethambutol Hydrochloride Ethyl-p-Aminobenzoate Ethylenediaminetetraacetic Acid Etodolac Ethyl Morphine

Famotidine Fenfluramine Ferrous(II) Sulfate Heptahydrate Fenoprofen Calcium Salt Hydrate Flufenamic Acid Flunitrazepam Flunisolide Flurandrenolide Flurazepam Dihydrochloride Furosemide Gemfibrozil Gentamicin Sulfate Granules Gentisic Acid Glutathione Reduced Glybenclamide Glucose Griseofulvin Halcinonide Heroin Hydrochloride Hexachlorophene Hypnovel (Cyclobarbital) Hippuric Acid Histamine Hydralazine Hydrochloride (1R,9S)-(-)-β-Hydrastine Hydroflumethiazide Hydromorphone Hydrocodone Hydroxocobalamin Hydrochloride a-Hydroxyhippuric Acid Hydroxyzine Dihydrochloride α-Hydroxyalprazolam 17α-Hydroxyprogesterone Hydrocortisone Hydrochlorothiazide Hypoxanthine

BIBLIOGRAPHY

 Moolchan, E., et al, "Saliva and Plasma Testing for Drugs of Abuse: Comparison of the Disposition and Pharmacological Effects of Cocaine", Addiction Research Center, IRP, NIDA, NIH, Baltimore, MD. As presented at the SOFT-TIAFT meeting October 1998.

- Kim, I, et al, "Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration", Clin Chem, 2002 Sept.; 48 (9), pp 1486-96.
- 3. Schramm, W. et al, "Drugs of Abuse in Saliva: A Review," J Anal Tox, 1992 Jan-Feb; 16 (1), pp 1-9
- McCarron, MM, et al, "Detection of Phencyclidine Usage by Radioimmunoassay of Saliva," J Anal Tox 1984 Sep-Oct.; 8 (5), pp 197-201.
- 5. Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735
- Ham, Becky (December 2002). "Signs of smoking linger longer in menthol smokers". Center for the Advancement of Health. Science Blog. Archived from the original on 17 March 2010. Retrieved 17 March 2010.
- 7. News, BBC (2007-03-17). "Race role' in tobacco smoke risk". BBC NEWS. Retrieved 2007-03-18.
- 8. Cone, EJ, "Saliva Testing for Drugs of Abuse," Ann NY Acad Sci, 1993;694:pp120

Distributed by:

CLIAwaived, Inc. 11578 Sorrento Valley Road Suite 25/26 San Diego, CA 92121 858-481-5031 www.CLIAwaived.com



Effective date: 03/20/2018